Exposure to electronic cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model.

Sussan TE, Gajghate S, Thimmulappa RK, Ma J, Kim JH, Sudini K, Consolini N, Cormier SA, Lomnicki S, Hasan F, Pekosz A, Biswal S. · 2015

Read Exposure to electronic cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model. by Sussan TE, Gajghate S, Thimmulappa RK, Ma J, Kim JH, Sudini K, Consolini N, Cormier SA, Lomnicki S, Hasan F, Pekosz A, Biswal S. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4317176.txt.

Introduction

Thomas E. Sussan and eleven co-authors exposed mice to electronic cigarette vapor and found their lungs defended themselves worse against infection. Their study appeared in PLoS ONE in 2015. E-cigarettes had surged in popularity on a healthy image, yet direct tests of their effects in living animals were almost absent.

The vapor carried a very large load of free radicals per puff, and exposed mice reached blood nicotine levels like those of human users. Two weeks of exposure raised oxidative stress and mild lung inflammation. Challenged with bacteria and flu virus afterward, exposed mice cleared the bacteria more slowly and fared worse against the virus. The results challenge the harmless label on vaping.

Catalog record

CREATORSussan TE, Gajghate S, Thimmulappa RK, Ma J, Kim JH, Sudini K, Consolini N, Cormier SA, Lomnicki S, Hasan F, Pekosz A, Biswal S.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4317176

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Exposure to Electronic Cigarettes Impairs Pulmonary Anti-Bacterial and Anti-Viral Defenses in a Mouse Model By Thomas E. Sussan, Sachin Gajghate, Rajesh K. Thimmulappa, Jinfang Ma, Jung-Hyun Kim, Kuladeep Sudini, Nicola Consolini, Stephania A. Cormier, Slawo Lomnicki, Farhana Hasan, Andrew Pekosz, Shyam Biswal Published in: PLoS ONE DOI: 10.1371/journal.pone.0116861 ABSTRACT Electronic cigarettes (E-cigs) have experienced sharp increases in popularity over the past five years due to many factors, including aggressive marketing, increased restrictions on conventional cigarettes, and a perception that E-cigs are healthy alternatives to cigarettes. Despite this perception, studies on health effects in humans are extremely limited and in vivo animal models have not been generated. Presently, we determined that E-cig vapor contains 7x1011 free radicals per puff. To determine whether E-cig exposure impacts pulmonary responses in mice, we developed an inhalation chamber for E-cig exposure. Mice that were exposed to E-cig vapor contained serum cotinine concentrations that are comparable to human E-cig users. E-cig exposure for 2 weeks produced a significant increase in oxidative stress and moderate macrophage-mediated inflammation. Since, COPD patients are susceptible to bacterial and viral infections, we tested effects of E-cigs on immune response. Mice that were exposed to E-cig vapor showed significantly impaired pulmonary bacterial clearance, compared to air-exposed mice, following an intranasal infection with Streptococcus pneumonia. This defective bacterial clearance was partially due to reduced phagocytosis by alveolar macrophages from E-cig exposed mice. In response to Influenza A virus infection, E-cig exposed mice displayed increased lung viral titers and enhanced virus-induced illness and mortality. In summary, this study reports a murine model of E-cig exposure and demonstrates that E-cig exposure elicits impaired pulmonary anti-microbial defenses. Hence, E-cig exposure as an alternative to cigarette smoking must be rigorously tested in users for their effects on immune response and susceptibility to bacterial and viral infections. INTRODUCTION Electronic cigarettes (E-cigs) have grown rapidly in popularity since first coming to the US market in 2007. The E-cig market for 2013 was approximately $1.7 billion, and US sales of E-cig products are expected to surpass tobacco products in a decade. Recent surveys indicate that use of E-cigs by adults in the US quadrupled between 2009 and 2010 [1], and is currently at 3.4% [2]. More than 700,000 individuals have switched from traditional cigarettes to electronic cigarettes. Although E-cigs were originally marketed as smoking cessation aids, E-cig use is also gaining popularity among never smokers, who now constitute a substantial portion of the E-cig market. Use among teenagers doubled between 2011 and 2012 [3], with an estimated 1.78 million middle and high school students using E-cigs, which suggests that E-cigs are an emerging public health issue. While cigarette smoke contains more than 5,000 different chemicals, E-cig vapor consists of relatively few constituents. The primary ingredient in E-cig vapor is a stabilizing agent, typically propylene glycol and/or glycerol, which is vaporized through delivery of an electric current to the E-cig cartridge. These vapor droplets carry nicotine and added flavors, such as menthol, piña colada, and strawberry. Because E-cigs do not produce any combustion products or tar, the perception remains, both among the general public and many physicians, that E-cigs are indeed a safer alternative to conventional cigarettes. Analyses of E-cig vapor have identified many different chemicals that could be potentially toxic or carcinogenic, including particulates, formaldehyde, nitrosamines, metals, carbonyls, volatile organic compounds, and polycyclic aromatic hydrocarbons; although these compounds are generally reported to be lower than in cigarette smoke [4–9]. Additionally, the levels of several of these toxicants are increased after vaporization, due to heat and/or voltage generated by the battery [10]. A recent in vitro study revealed that exposure of lung epithelial cells to E-cig-conditioned medium induces a gene expression signature similar to tobacco smoke [11]. However, human studies on effects of E-cig exposure are limited to very short-term responses, and there are no in vivo animal studies. Based on current information, the Food and Drug Administration (FDA), the World Health Organization (WHO), and the European Respiratory Society have indicated that electronic cigarettes are not considered a safe alternative to smoking. Furthermore, recent studies indicate that E-cigs may not be an effective therapy for smoking cessation [12]. Cigarette smoke contains 1014 free radicals/puff [13] and causes oxidative damage, inflammation and apoptosis, which drive the pathogenesis of chronic obstructive pulmonary disease (COPD). More importantly, cigarette smoke exposure impairs innate and adaptive immune responses against bacteria and viruses, which predispose to COPD exacerbations, a major contributor to COPD-related morbidity, mortality and health care costs [14]. The goal of our current study was to develop a murine model of E-cig exposure and to assess the pulmonary defenses against bacterial or viral infection. We demonstrated that E-cig vapor is surprisingly a rich source of free radicals, and E-cig exposure resulted in airway inflammation, oxidative stress, and impaired anti-bacterial and anti-viral responses that include increased bacterial burden and viral titers in lungs, impaired bacterial phagocytosis, and increased virus-induced morbidity and mortality. This impaired anti-microbial response indicates that E-cig exposure is not a safe alternative to cigarette smoking. METHODS Animals Male C57BL/6 (age 8 wks) were purchased from NCI Frederick. All mice were housed under controlled conditions for temperature and humidity in a specific pathogen free facility, using a 12 h light/dark cycle. Mice were randomly assigned to each treatment group. All experimental protocols were performed in accordance with the standards established by the US Animal Welfare Acts, as set forth in NIH guidelines and in the Policy and Procedures Manual of the Johns Hopkins University Animal Care and Use Committee. All procedures were approved by the Johns Hopkins University Animal Care and Use Committee. Animals were monitored daily, and any mice exhibiting signs of distress were euthanized. Mice were anesthetized via inhalation of isofluorane, and all animals were euthanized by inhalation of carbon dioxide followed by exsanguination. Animal exposure Mice were exposed to NJOY menthol bold (1.8% nicotine) rechargeable E-cigs, except where indicated. A subset of mice was exposed to NJOY traditional bold (1.8% nicotine) rechargeable E-cigs. E-cig vapor was generated using the Jaeger-Baumgartner CSM 2080 (CH Technologies), in which a 2 s puff (35ml) was taken every 10 s and mixed with dilution air via a pump set at 1.05 L/min. Mice were exposed via a whole-body exposure system for 1.5 h, twice per day for 2 wks. Exposure level was observed in real time via a MicroDust Pro (Casella CEL), and exposure was assessed by measuring serum cotinine at 1 h after exposure. The smoke machine has a maximum capacity of 30 E-cigs that can be loaded onto a carousel that rotates at 1 RPM. For each exposure, we loaded 6 E-cigs, which were evenly spaced so that each E-cig was puffed for 2 s, once per minute, for a total of 6 puffs per minute. E-cig batteries were charged prior to each exposure and E-cig cartridges were replaced each week. The lifespan of each cartridge varied considerably, so they were also replaced whenever the real-time exposure monitor detected a decrease in output of a specific E-cig. The nephelometer readings averaged 1613±165 mg/m3 throughout the exposures, although it should be noted that the nephelometer was not calibrated for E-cig vapor. Thus, these readings were simply used to maintain consistent exposure rather than to

Read the complete text